Haleos Labs Limited (HALEOSLABS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002809,
    "name": "Haleos Labs Limi",
    "stock_name": "Haleos Labs Limi",
    "full_name": "Haleos Labs Limited",
    "name_url": "stocks-analysis/haleos-labs-limi",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,510.00",
    "chg": -11,
    "chgp": "-0.72%",
    "dir": -1,
    "prev_price": "1,521.00",
    "mcapval": "457.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540679,
    "symbol": "HALEOSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE320X01016",
    "curr_date": "Jun 03, 03:30 PM",
    "curr_time": "23:16 PM",
    "last_traded_at": "Jun 03, 03:30 PM IST",
    "bse_nse_vol": "1.45 k",
    "exc_status": "Active",
    "traded_date": "Jun 03, 2026",
    "traded_date_str": "2026 06 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/haleos-labs-limi-1002809-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Haleos Labs Limited Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-lower-circuit-amid-heavy-selling-pressure-4026083",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HaleosLabsLimit_stocks_hitting_lower_circuit_4026083.png",
        "date": "2026-06-01 10:00:31",
        "description": "At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Haleos Labs Limited Faces Sharp Financial Downturn Amidst Strong Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-faces-sharp-financial-downturn-amidst-strong-market-returns-4025014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HaleosLabsLimit_fintrenddot_4025014.png",
        "date": "2026-06-01 08:00:56",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors."
      },
      {
        "title": "Are Haleos Labs Limited latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-haleos-labs-limited-latest-results-good-or-bad-4023944",
        "imagepath": "",
        "date": "2026-05-30 19:53:48",
        "description": "Haleos Labs Limited's latest financial results for Q4 FY26 reflect significant operational challenges and margin pressures. The company reported net sales of ₹75.14 crores, which represents a decline of 15.68% year-on-year and marks the lowest quarterly revenue in recent periods. This decline is accompanied by a substantial drop in net profit, which fell to ₹0.44 crores, reflecting an 85.19% decrease compared to the same quarter last year.\n\nThe operating profit margin, excluding other income, contracted sharply to 5.54% from 14.82% in the previous quarter, indicating severe margin compression. This deterioration in profitability is further highlighted by the profit after tax margin, which fell to 0.45%, the lowest in years. The company's operational metrics suggest that elevated employee costs and a significant increase in the tax rate to 61.54% have contributed to the decline in profitability.\n\nDespite a p..."
      },
      {
        "title": "Haleos Labs Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Resilience",
        "link": "https://www.marketsmojo.com/news/result-analysis/haleos-labs-q4-fy26-sharp-profit-decline-raises-concerns-despite-revenue-resilience-4022854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_quaterlyResult_4022854.png",
        "date": "2026-05-29 22:24:32",
        "description": "Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-4018046",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_mojoScore_4018046.png",
        "date": "2026-05-28 10:10:04",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance."
      },
      {
        "title": "Haleos Labs Limited Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-technical-momentum-shifts-signal-bullish-outlook-amid-mixed-indicators-4010000",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_technicaldot_4010000.png",
        "date": "2026-05-25 08:03:09",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential."
      },
      {
        "title": "Haleos Labs Limited Technical Momentum Shifts Signal Mildly Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-technical-momentum-shifts-signal-mildly-bullish-outlook-4004382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_technicaldot_4004382.png",
        "date": "2026-05-22 08:03:50",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Sell to Hold. The stock’s recent performance, buoyed by bullish signals on multiple timeframes, contrasts with some cautionary monthly indicators, reflecting a nuanced outlook for investors."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-by-marketsmojo-3995432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_mojoScore_3995432.png",
        "date": "2026-05-17 10:10:03",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of the company's performance and outlook."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Haleos Labs Limited to 52-Week High of Rs 1738.35",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-new-52-week-high-at-rs173835-3985542",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_priceRelatedfactors_3985542.png",
        "date": "2026-05-11 10:37:37",
        "description": "Surging past its previous peaks, Haleos Labs Limited touched a new 52-week high of Rs 1738.35 on 11 May 2026, marking a significant milestone amid a challenging broader market environment. The stock’s recent momentum is underpinned by a confluence of bullish technical indicators, signalling robust price strength despite the Sensex’s ongoing weakness."
      }
    ],
    "total": 453,
    "sid": "1002809",
    "stock_news_url": "https://www.marketsmojo.com/news/haleos-labs-limited-1002809"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "30-May-2026",
      "details": "Enclosed - Annual Secretarial Compliance Report F26",
      "source": "BSE"
    },
    {
      "caption": "Financial Results (Q4/F26)",
      "datetime": "30-May-2026",
      "details": "Enclosed financial results for the quarter and year ended 31st March 2026.",
      "source": "BSE"
    },
    {
      "caption": "Auditors Appointment",
      "datetime": "29-May-2026",
      "details": "Enclosed are the details related to the appointment of Statutory Auditors and Cost Auditors.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Haleos Labs Limited has declared <strong>15%</strong> dividend, ex-date: 24 Sep 25",
          "dt": "2025-09-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Haleos Labs Limited Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight

2026-06-01 10:00:31

At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price.

Read full news article

Haleos Labs Limited Faces Sharp Financial Downturn Amidst Strong Market Returns

2026-06-01 08:00:56

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors.

Read full news article

Are Haleos Labs Limited latest results good or bad?

2026-05-30 19:53:48

Haleos Labs Limited's latest financial results for Q4 FY26 reflect significant operational challenges and margin pressures. The company reported net sales of ₹75.14 crores, which represents a decline of 15.68% year-on-year and marks the lowest quarterly revenue in recent periods. This decline is accompanied by a substantial drop in net profit, which fell to ₹0.44 crores, reflecting an 85.19% decrease compared to the same quarter last year. The operating profit margin, excluding other income, contracted sharply to 5.54% from 14.82% in the previous quarter, indicating severe margin compression. This deterioration in profitability is further highlighted by the profit after tax margin, which fell to 0.45%, the lowest in years. The company's operational metrics suggest that elevated employee costs and a significant increase in the tax rate to 61.54% have contributed to the decline in profitability. Despite a p...

Read full news article

Haleos Labs Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Resilience

2026-05-29 22:24:32

Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects.

Read full news article

Haleos Labs Limited is Rated Hold

2026-05-28 10:10:04

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Read full news article

Haleos Labs Limited Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators

2026-05-25 08:03:09

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential.

Read full news article

Haleos Labs Limited Technical Momentum Shifts Signal Mildly Bullish Outlook

2026-05-22 08:03:50

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Sell to Hold. The stock’s recent performance, buoyed by bullish signals on multiple timeframes, contrasts with some cautionary monthly indicators, reflecting a nuanced outlook for investors.

Read full news article

Haleos Labs Limited is Rated Hold by MarketsMOJO

2026-05-17 10:10:03

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Read full news article

Broad-Based Technical Strength Lifts Haleos Labs Limited to 52-Week High of Rs 1738.35

2026-05-11 10:37:37

Surging past its previous peaks, Haleos Labs Limited touched a new 52-week high of Rs 1738.35 on 11 May 2026, marking a significant milestone amid a challenging broader market environment. The stock’s recent momentum is underpinned by a confluence of bullish technical indicators, signalling robust price strength despite the Sensex’s ongoing weakness.

Read full news article

View All News